ELAN Stock Analysis: Buy, Sell, or Hold?
ELAN - Elanco Animal Health Incorporated Common Stock
$19.86
-1.78 (-8.23%)
▼
5d:
-16.03%
30d:
-14.14%
90d:
-20.97%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
ELAN is down 13.0% this week, but smart money is accumulating calls. Top strike: $27 2026-06-18 with 6,110 OI. Call ratio: 94% View Scanner →
Strength: 10.0/10
Get Alerted When ELAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ELAN this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.99
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$23.59
15.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ELAN is currently trading at $19.86, which is considered oversold relative to its 30-day fair value range of $21.72 to $23.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.4) compared to its historical average (21.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ELAN is in a downtrend. The price is currently testing key support at $20.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: ELAN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $29.86 (+50.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ELAN is in a downtrend. The price is currently testing key support at $20.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: ELAN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $29.86 (+50.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.72 -
$23.91
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding ELAN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 50.3% below Wall St target ($29.86)
- CAUTION: 5-day price weakness (-16.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$21.72 -
$23.91
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$20.67
Resistance Level
$26.29
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.37
Wall Street Target
$29.86
(+50.3%)
Revenue Growth (YoY)
14.9%
Earnings Growth (YoY)
-15.4%
Profit Margin
-5.0%
Valuation Discount vs History
-8.6% cheaper
PE vs Historical
16.4 vs 21.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.6%
(market-implied from PE analysis)
1-Year Target
$18.15
(-9%)
2-Year Target
$16.59
(-17%)
3-Year Target
$15.16
(-24%)
3-Yr Target (if PE normalizes)
(PE: 16→22)
$19.91
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 11.7%)
$37.28
(+88%)
Base:
(SPY PE: 16.4, Growth: 11.7%)
$27.66
(+39%)
Bear:
(PE: 13.9, Growth: 11.7%)
$23.51
(+18%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.4 to 21.5
Stabilization Target:
$26.08
(+31.3%)
PE Expansion Potential:
+31.3%
Share & Embed Analysis
Last updated: May 18, 2026 4:06 AM ET
Data refreshes hourly during market hours. Next update: 5:06 AM
Data refreshes hourly during market hours. Next update: 5:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELAN showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Lawrence Erik Kurzius
BUY
10000 shares
2025-12-12
Jeffrey N Simmons
BUY
22000 shares
2025-12-11
Rajeev A Modi
BUY
4500 shares
2025-12-11
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
Advanced ELAN Option Strategies
Professional options setups generated by AI based on today's ELAN price and gamma walls.
